» Articles » PMID: 38283198

Bacteria-Based Nanoprobes for Cancer Therapy

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2024 Jan 29
PMID 38283198
Authors
Affiliations
Soon will be listed here.
Abstract

Surgical removal together with chemotherapy and radiotherapy has used to be the pillars of cancer treatment. Although these traditional methods are still considered as the first-line or standard treatments, non-operative situation, systemic toxicity or resistance severely weakened the therapeutic effect. More recently, synthetic biological nanocarriers elicited substantial interest and exhibited promising potential for combating cancer. In particular, bacteria and their derivatives are omnipotent to realize intrinsic tumor targeting and inhibit tumor growth with anti-cancer agents secreted and immune response. They are frequently employed in synergistic bacteria-mediated anticancer treatments to strengthen the effectiveness of anti-cancer treatment. In this review, we elaborate on the development, mechanism and advantage of bacterial therapy against cancer and then systematically introduce the bacteria-based nanoprobes against cancer and the recent achievements in synergistic treatment strategies and clinical trials. We also discuss the advantages as well as the limitations of these bacteria-based nanoprobes, especially the questions that hinder their application in human, exhibiting this novel anti-cancer endeavor comprehensively.

Citing Articles

Genetically engineered gas vesicle proteins with proliferative potential for synergistic targeted tumor therapy.

Lin L, Du Y, Wang Y, Luo Y, Jiang F, Yang H RSC Adv. 2025; 15(1):157-166.

PMID: 39758902 PMC: 11694345. DOI: 10.1039/d4ra07532c.


Enhancing photothermal therapy of tumors with image-guided thermal control of gene-expressing bacteria.

Zeng F, Du M, Yang Y, Fang J, Wang Y, Goh M Theranostics. 2024; 14(15):5945-5964.

PMID: 39346533 PMC: 11426242. DOI: 10.7150/thno.98257.


Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy.

Gholami A, Mohkam M, Soleimanian S, Sadraeian M, Lauto A Microsyst Nanoeng. 2024; 10:113.

PMID: 39166136 PMC: 11333603. DOI: 10.1038/s41378-024-00743-z.

References
1.
Ikonomidis G, Paterson Y, Kos F, Portnoy D . Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J Exp Med. 1994; 180(6):2209-18. PMC: 2191788. DOI: 10.1084/jem.180.6.2209. View

2.
Wang W, Lu M, Kuan Y, Lee C . The treatment of mouse colorectal cancer by oral delivery tumor-targeting Salmonella. Am J Cancer Res. 2015; 5(7):2222-8. PMC: 4548333. View

3.
Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, Casadevall A, Dadachova E . Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(21):8668-73. PMC: 3666740. DOI: 10.1073/pnas.1211287110. View

4.
Heydari Z, Rahaie M, Alizadeh A, Agah S, Khalighfard S, Bahmani S . Effects of Lactobacillus acidophilus and Bifidobacterium bifidum Probiotics on the Expression of MicroRNAs 135b, 26b, 18a and 155, and Their Involving Genes in Mice Colon Cancer. Probiotics Antimicrob Proteins. 2018; 11(4):1155-1162. DOI: 10.1007/s12602-018-9478-8. View

5.
Le D, Wang-Gillam A, Picozzi V, Greten T, Crocenzi T, Springett G . Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015; 33(12):1325-33. PMC: 4397277. DOI: 10.1200/JCO.2014.57.4244. View